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Abstract
Little is known about the molecular anomalies involved
in the development and progression of malignancy of
pancreatic endocrine tumors (PETs). A recently identi-
fied member of the Ras family, Ras homologuemember
I (ARHI ), has been shown to be involved in breast,
ovary, and thyroid carcinogenesis. Unlike other mem-
bers, it acts as a tumor suppressor gene that inhibits
cell growth. Here we analyzed the mRNA expression of
ARHI in 52 primary PETs and 16 normal pancreata using
quantitative reverse transcription-polymerase chain
reaction. ARHI expression showed a statistically sig-
nificant difference between either normal pancreas
or well-differentiated endocrine tumors (WDET) and
poorly differentiated endocrine carcinomas (PDECs)
(P < .001 and P < .001, respectively). Moreover, ARHI
expression among WDEC samples was more heteroge-
neous than inWDET, with several tumors showing level
of expression analogous to that observed in PDECs. A
significant correlation between lower ARHI expres-
sion and shorter survival (P = .020) was identified, and
a low ARHI expression was associated to a shorter
time to progression (P < .001), even considering the
proliferation index Ki67 in the multivariate analysis.
ARHI is involved in PET progression. Its mRNA ex-
pression seemed to be a prognostic factor for dis-
ease outcome and, in association with the proliferative
index Ki67, a predictor for a rapid tumor relapse.
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Introduction
Pancreatic endocrine tumors (PETs) are a heterogeneous
group of neoplasms that are clinically classified as func-
tioning or nonfunctioning according to the presence of
symptoms due to hormone hypersecretion. According to
the World Health Organization classification [1], PETs,
whether functioning or not, are classified into three cate-
gories: 1) well-differentiated endocrine tumors (WDETs),
2) well-differentiated endocrine carcinomas (WDECs), and 3)
poorly differentiated endocrine carcinomas (PDECs). The
WDET category is further distinguished into two subgroups
with either benign or uncertain clinical behavior [1]. Carci-
nomas are characterized by the presence of invasion or metas-
tases, and among them PDECs are highly aggressive and
show a poorer outcome compared with WDECs [1]. To date,
little is known about the molecular pathways and anomalies
involved in PET development and progression [2].
Ras homologue member I (ARHI ) is one of the first iden-
tified tumor suppressors belonging to the Ras superfamily. It
encodes a 26-kDa GTPase with 50% to 60% amino acid
homology to Ras but exerts opposite functions that inhibit
cell growth, motility, and invasion [3–5]. Notably, it has been
shown that ARHI underexpression correlated with breast tumor
progression as well as reduced progression-free survival in
ovarian cancer [6,7].
In the present work, we analyzed the expression of ARHI in
52 PETs and 16 normal pancreata to assess possible clinical-
pathological correlations with tumor differentiation, proliferation
rate, and clinical behavior including time to progression (TTP)
and survival.
Materials and Methods
Materials
The study involved 52 primary PETs (22WDETs, 26WDECs,
and 4 PDECs), obtained from patients that underwent either
explorative or radical surgery with their informed consent
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(Table W1), and 16 normal samples (Table W2). These
included 12 pancreatic bulk tissues and four human pancreatic
islets of Langerhans cell preparations [8]. PETs were diag-
nosed by histopathological and cell marker analysis and
classified according to World Health Organization criteria [1].
Total RNA was prepared from 10 to 20 cryostat sections
(40 mm thick) of snap-frozen tissue, checking the cellularity
every four sections. Tissue sections were placed in 4 M
guanidine thiocyanate containing 0.1 M 2-mercaptoethanol
and centrifuged through a CsCl2 gradient. RNA quality was
assessed by using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA). cDNA was synthesized from
1 mg of total RNA using random primers and the Super-
script II reverse transcription kit (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions.
Quantitative Reverse Transcription Polymerase
Chain Reaction
QuantitativeReverse Transcription polymerase chain reac-
tion (PCR) mRNA expression analysis was performed on ABI
PRISM 7000 Sequence Detection System (Applied Biosys-
tems, Foster City, CA) using SYBR green PCR Master Mix
(Applied Biosystems) according to the manufacturer’s in-
structions. Oligonucleotide primers used were the following:
ARHI-F, AGAAAGGGGTCTCCTGCTG, and ARHI-R, GCA-
GCTTCTGTTCCTTGGAG; b-actin-F, GGAGTCCTGTGG-
CATCCACG, and b-actin-R, CTAGAAGCATTTGCGGTGGA.
b-Actin transcript level (RefSeq ID NM_001101) was used to
normalize the samples.
Calibration curves of each couple of primers were obtained
by serial dilution of cDNA. Expression data were analyzed by
the comparative threshold cycle (Ct) method accordingly to
User Bulletin No. 2 (Applied Biosystems). Results were
expressed in terms of the DDCt value and obtained as fol-
lows: DCtARHI = CtARHI  Ctb-actin and DDCtARHI = jjDCtARHI 
max(DCtARHI)||, where CtARHI and Ctb-actin represent the
comparative threshold cycles for ARHI and b-actin, respec-
tively. All experiments were performed in duplicate.
Time to Progression and Survival Evaluation
Patients were monitored every 3- months with contrast-
enhanced CTscan, clinical evaluation of symptoms and body
weight, and measurement of blood parameters and tumor
markers. Time to progression was defined as the interval
from the surgery until disease progression, as previously
described [9]. Survival was calculated from the date of
diagnosis to the date of death, and only deaths from the
disease were considered. ARHI expression was categorized
by applying a cutoff level defined as the lowest DDCt mea-
sured in the normal control samples. Therefore, tumors with
DDCt below this cutoff were considered to have a low ARHI
expression, whereas those with DDCt above the cutoff were
considered as having a normal level of expression.
Statistical Analysis
The statistical significance of the differences between
subgroups was investigated by either logistic regression
analysis or the Mann-Whitney test. Survival and TTP data
were analyzed using Kaplan Meier function and the log-rank
test for univariate analyses or Cox proportional hazard re-
gression. All P values were two sided and considered sig-
nificant when less than .05. All the analyses were performed
using R software v. 2.1.1 and Survival package (http://
www.R-project.org).
Results and Discussion
The Ras homologue member I (ARHI ) is a tumor suppressor
gene and a member of the Ras family that is able to nega-
tively regulate the Ras/mitogen-activated protein kinases
(MAPK) signaling pathway inhibiting cancer cell growth [3].
Wang et al. have shown that ARHI was frequently down-
regulated in breast carcinoma and was negatively associated
with tumor progression [7]. More interestingly, ARHI expres-
sion was associated with expression of p21WAF/CIP1 and
prolonged disease-free survival in epithelial ovarian cancer
[6]. In addition, it has been shown that ARHI silencing could
contribute to the carcinogenesis of follicular thyroid carcino-
mas, which are the most common endocrine cancers [10].
We analyzed themRNA level of ARHI by quantitative real-
time PCR in 52 PETs to identify possible correlations with
clinical-pathological parameters (Tables W1 and W3). Logis-
tic regression analysis identified a significant correlation be-
tween ARHI expression and tumor differentiation (odds ratio,
0.916; 95% confidence interval, 0.894–0.938; P < .001). In
fact, PDEC samples showed a significant lower expression
Figure 1. Box and whiskers plot of ARHI mRNA expression in 52 PETs and
16 normal pancreatic samples. Dotted line indicate the cutoff level used to
distinguish samples with low (below the line) and normal (above the line)
ARHI mRNA expression. WDET, well-differentiated tumor; WDEC, well-
differentiated carcinoma; PDEC, poorly differentiated carcinoma.
Table 1. Multivariate Analysis of TTP in PETs.
Hazard Ratio (95% Confidence Interval) P
Low ARHI expression 4.0 (1.5–11.1) .007
Ki67 z5% 8.3 (2.8–24.8) .0002
Hazard ratio represents an estimate of the ratio of mortality rate in patients
with low ARHI expression versus patients with normal ARHI expression, or
patients with proliferation index Ki67 <5% versus patients with Ki67 z5%.
Cox proportional hazard model was used with simultaneous inclusion of all
factors shown.
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of ARHI compared with normal pancreas and WDET (Mann-
Whitney test, P < .001 and P < .001, respectively), whereas
no significant difference was observed between WDET and
WDEC. However, the expression of ARHI among the WDEC
samples was heterogeneous, with several tumors showing
levels of expression analogous to those observed in PDEC
samples (Figure 1). Notably, patients with WDEC with low
ARHI expression showed a median TTP of 30 months
versus 49 months observed in WDEC patients with normal
ARHI expression, although this difference was not statisti-
cally significant.
The correlation between ARHI expression and survival or
TTP was tested in 47 and 49 patients, respectively, for which
these data were available. A shorter survival was associated
with tumor differentiation (P < .001), low ARHI expression
(P = .020; Figure W1) and high proliferative index (Ki67  5%;
P < .001). The association between survival and Ki67 re-
mained significant when PDECs were excluded from the
analysis (P = .016), confirming the reported prognostic value
of proliferative index [1,11]. Similarly, a shorter TTP was
associated with tumor differentiation (P < .001), reduced
ARHI expression (P < .001; FigureW2), and high proliferative
index (P < .001). In addition, shorter TTP was found to be
associated with low ARHI expression (P = .036) and high
proliferation index (P = .001) when only WDET and WDEC
were included in the analysis.
Notably, multivariate analysis showed that ARHI ex-
pression was an independent prognostic factor for TTP in
association with the proliferative index Ki67 (Cox proportional
hazard; Table 1, Figure 2), which is the most informative
molecular marker of PEToutcome [11]. In particular, patients
with low ARHI expression showed a significantly higher
hazard ratio for disease progression compared with those
with normal ARHI expression. Moreover, all the seven
patients with low ARHI expression and high proliferation
index showed tumor progression after a shorter time.
These findings suggest that ARHI is involved in PET
progression. In addition, ARHI mRNA level seems to be
a prognostic factor for disease outcome and, in association
with the proliferative index Ki67, a predictor of a rapid
tumor relapse.
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Table W1. Supplementary PET Clinical-Pathological Data and ARHI mRNA Expression.
Sample Tumor Type Diagnosis Follow-up (months) Progression* TTP* (months) Outcome Ki67 (%) ARHI DDCty
1 NF WDEC 58 Yes 52 DOD 5 12.24
2 NF PDEC 12 Yes 6 DOD 30 6.61
3 NF WDEC 73 Yes 36 AWD 10 7.94
4 NF WDET 88 No AW 2 10.87
5 NF WDEC 49 Yes 22 AWD 8 4.49
6 F WDET 50 No AW 2 10.31
7 F WDEC 25 Yes 12 DOD 17 10.10
8 NF WDET 89 No AW 2 11.33
9 NF WDEC 71 Yes 14 DOD 7 4.09
10 NF WDET 48 No AW 2 10.53
11 NF WDEC 31 Yes 8 AWD 5 2.74
12 NF WDEC 58 No AW 3 13.57
13 F WDET 48 No AW 1 10.65
14 NF WDEC 32 Yes 25 AWD 3 11.40
15 NF PDEC 6 Yes 6 DOD 40 6.10
16 NF WDEC 38 No AW 2 10.36
17 NF WDEC 91 Yes 36 DOD 2 11.47
18 NF WDEC 37 No AW 5 11.51
19 F WDET 47 No AW 1 10.50
20 NF WDET 76 No AW 1 10.71
21 NF WDET 66 No DOC 2 10.83
22 F WDEC 45 No AW 3 9.13
23 NF WDET 25 No AW 2 9.37
24 NF WDET 22 No AW 2 8.53
25 NF WDET 30 No AW 1 10.24
26 NF WDEC 38 No AW 2 11.48
27 NF WDET 43 No AW 2 13.22
28 NF WDEC na na na na 2 7.09
29 NF WDEC 45 No AW 5 12.56
30 NF WDET 162 No AW 1 11.32
31 NF WDEC 32 No AW 2 3.91
32 NF WDEC 68 Yes 24 DOD 17 11.13
33 NF WDEC 76 No AW 2 5.82
34 NF WDET 56 No AW 2 12.65
35 NF PDEC 13 Yes 4 DOD 25 4.77
36 NF WDEC 4 Yes 2 DOD 1 11.61
37 F WDET 55 No AW 2 10.84
38 F WDET 200 No AW 2 11.83
39 NF WDEC 55 Yes 36 DOD 5 9.45
40 NF WDET 60 No AW 1 3.01
41 NF WDEC na na na na 2 3.27
42 NF PDEC 13 Yes 7 DOD 40 0.00
43 NF WDEC 55 Yes 24 DOD 2 5.38
44 NF WDET 164 No AW 5 13.32
45 NF WDEC 3 No DOC 3 5.10
46 NF WDET 135 No AW 1 11.06
47 F WDET 35 No AW 2 11.54
48 NF WDET 22 No AW 2 10.66
49 NF WDEC 53 No AW 2 6.52
50 NF WDEC 104 Yes 104 AW 3 12.28
51 NF WDEC 91 Yes 49 AWD 2 13.68
52 NF WDET na na na na 1 8.29
NF, nonfunctioning; F, functioning; WDET, well-differentiated endocrine tumor; WDEC, well-differentiated endocrine carcinoma, PDEC: poorly differentiated
endocrine carcinoma; na, not available; AW, alive and well; AWD, alive with disease; DOD, dead of disease; DOC, dead of other cause.
*Time to progression calculated as the interval from surgery to disease progression.
yDDCtARHI = jjDCtARHI  max(DCtARHI)jj, where CtARHI and Ctb-actin represent the comparative threshold cycle for ARHI and b-actin, respectively.
Table W2. ARHI mRNA Expression in Normal Pancreatic Bulk Tissues and
Islets.
Sample* ARHI DDCty
N1 11.06
N2 9.07
N3 9.39
N4 9.41
N5 9.47
N6 9.58
N7 9.69
N8 9.81
N9 10.11
N10 10.26
N11 10.44
N12 11.81
I1 8.09
I2 12.01
I3 8.14
I4 8.71
*N1 to N12: normal pancreatic bulk tissues; I1 to I4: normal pancreatic islets.
yDDCtARHI = jjDCtARHI  max(DCtARHI)jj, where CtARHI and Ctb-actin represent
the comparative threshold cycle for ARHI and b-actin, respectively.
Table W3. ARHI and Ki67 Expression in Relation to Tumor Category and
Outcome.
No. of
patients*
Mean
Ki67 (%)
Mean
ARHI DDCty
Outcome
(DOD)z
WDET 20 2 10.62 0/20
WDEC 23 5 9.25 8/23
PDEC 4 34 4.37 4/4
*Only patients with survival data available are included.
yDDCtARHI = jjDCtARHI  max(DCtARHI)jj, where CtARHI and Ctb-actin represent
the comparative threshold cycle for ARHI and b-actin, respectively.
zOutcome: number of patients dead of disease (DOD).
Figure W1.
Figure W2.
